Category - Markets

Markets

EF Hutton starts Citius Pharmaceuticals at buy; PT $6

EF Hutton launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) a “buy” rating and $6 target price. The stock closed at $0.7340 on July 12. Citius is a pharmaceutical/biotechnology company with two late-stage assets...

July 15, 2024

Markets

Raymond James upgrades Alpha Cognition to outperform; PT to $2

Raymond James upgraded Alpha Cognition (CSE:ACOG) to “outperform” from “market perform” and raised its price target to C$2 from C$1 with the company’s PDUFA date less than 2 weeks away (July 27th). The stock closed at...

July 15, 2024

Markets

Rodman & Renshaw starts BioRestorative Therapies at buy; PT $15

Rodman & Renshaw launched coverage of BioRestorative Therapies (NASDAQ:BRTX) with a “buy” rating and $15 target price. The stock closed at $2.02 on June 26. BioRestorative develops therapeutic products using cell...

June 27, 2024

Markets

William Blair starts Solid Biosciences at OP

William Blair launched coverage of Solid Biosciences (NASDAQ:SLDB) with an “outperform” rating. The stock closed at $14.25 on March 27. Solid Biosciences is a development-stage biotechnology company transitioning to...

March 28, 2024

Markets

Sigyn announces reverse split to support uplist to Nasdaq

Sigyn Therapeutics (OTCQB:SIGY) announced a 1-for-40 reverse split. Sigyn’s common stock is expected to begin trading on a split-adjusted basis on OTCQB when the market opens on Jan. 31. As a result of the split...

January 30, 2024

Markets

Avenue Therapeutics Reaches Final Agreement with FDA for the Phase 3 Safety Study for IV Tramadol

Fortress Biotech (NASDAQ:FBIO) partner company, Avenue Therapeutics (NASDAQ:ATXI) announced that it reached a final agreement with the FDA on the Phase 3 safety study protocol and statistical analysis approach...

January 4, 2024

Developments Markets

Hepion reports restructuring and resignations; Brookline downgrades to hold and suspends target

Hepion Pharmaceuticals (NASDAQ:HEPA) announced a restructuring that, among other things, will suspend the enrollment of new patients in the Phase 2b ‘ASCEND-NASH’ clinical trial of its lead drug candidate, rencofilstat...

December 7, 2023

Markets

Evercore starts Gracell Biotech at OP

Evercore ISI initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with an “outperform” rating and no price target. The stock was quoted at $5.43 midday on Nov. 27. Gracell is developing a unique CAR-T construct...

November 27, 2023

Markets

Brookline starts Annovis Bio at buy; PT $35

Brookline Capital Markets initiated coverage of Annovis Bio (NASDAQ:ANVS) with a “buy” rating and price target of $35. The stock was quoted at $5.85 midday on Nov. 10. Annovis is developing treatments for...

November 10, 2023

Markets

AGP ups Myomo to buy; PT $4.60 from $2

Alliance Global Partners upgraded Myomo (NYSE:MYO) to “buy” and raised its price target to $4.60 from $2. The stock was quoted at $1.85 midday on Nov.8. Myomo develops and markets the MyoPro product line of lightweight...

November 8, 2023

Category - Markets

Subscribe